TY - JOUR T1 - Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers JF - medRxiv DO - 10.1101/2020.11.09.20228551 SP - 2020.11.09.20228551 AU - Peter Kremsner AU - Philipp Mann AU - Jacobus Bosch AU - Rolf Fendel AU - Julian J. Gabor AU - Andrea Kreidenweiss AU - Arne Kroidl AU - Isabel Leroux-Roels AU - Geert Leroux-Roels AU - Christoph Schindler AU - Mirjam Schunk AU - Thirumalaisamy P. Velavan AU - Mariola Fotin-Mleczek AU - Stefan Müller AU - Gianluca Quintini AU - Oliver Schönborn-Kellenberger AU - Dominik Vahrenhorst AU - Thomas Verstraeten AU - Lisa Walz AU - Olaf-Oliver Wolz AU - Lidia Oostvogels Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/09/2020.11.09.20228551.abstract N2 - There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from convalescent sera and preclinical studies has identified the viral Spike (S) protein as a key antigenic target for protective immune responses. We have applied an mRNA-based technology platform, RNActive®, to develop CVnCoV which contains sequence optimized mRNA coding for a stabilized form of S protein encapsulated in lipid nanoparticles (LNP). Following demonstration of protective immune responses against SARS-CoV-2 in animal models we performed a dose-escalation phase 1 study in healthy 18-60 year-old volunteers.This interim analysis shows that two doses of CVnCoV ranging from 2 μg to 12 μg per dose, administered 28 days apart were safe. No vaccine-related serious adverse events were reported. There were dose-dependent increases in frequency and severity of solicited systemic adverse events, and to a lesser extent of local reactions, but the majority were mild or moderate and transient in duration. Immune responses when measured as IgG antibodies against S protein or its receptor-binding domain (RBD) by ELISA, and SARS-CoV-2-virus neutralizing antibodies measured by micro-neutralization, displayed dose-dependent increases. Median titers measured in these assays two weeks after the second 12 μg dose were comparable to the median titers observed in convalescent sera from COVID-19 patients. Seroconversion (defined as a 4-fold increase over baseline titer) of virus neutralizing antibodies two weeks after the second vaccination occurred in all participants who received 12 μg doses.Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels.Based on these results, the 12 μg dose is selected for further clinical investigation, including a phase 2b/3 study that will investigate the efficacy, safety, and immunogenicity of the candidate vaccine CVnCoV.Competing Interest StatementPhilipp Mann, Mariola Fotin-Mleczek, Stefan Mueller, Gianluca Quintini, Dominik Vahrenhorst, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels are employees of CureVac AG Oliver Schoenborn-Kellenberger, Thomas Verstraeten received consultancy fees from CureVac AGClinical TrialNCT04449276Funding StatementCureVac AG Friedrich-Miescher-Str. 15 72076 Tuebingen GermanyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EC Tuebingen, Germany EC Gent, BelgiumAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data are referred to ER -